Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia

By Klisovic Rebecca B.   Blum William   Liu Zhongfa   Xie Zhiliang   Kefauver Cheryl   Huynh Lenguyen   Zwiebel James A.   Devine Steven M.   Byrd John C.   Grever Michael R.   Chan Kenneth K.   Marcucci Guido  

Leukemia and Lymphoma, Vol. 55, Iss. 6, 2014-06 ,pp. : 1332-1336

Informa Healthcare

Access to resources Recommend Favorite

Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia

By Walker Alison R.   Klisovic Rebecca B.   Garzon Ramiro   Schaaf Larry J.   Humphries Kristina   Devine Steven M.   Byrd John C.   Grever Michael R.   Marcucci Guido   Blum William  

Leukemia and Lymphoma, Vol. 55, Iss. 6, 2014-06 ,pp. : 1304-1308

Informa Healthcare

Access to resources Recommend Favorite

Prognostic value of the expression of phosphatase and tensin homolog and CD44 in elderly patients with refractory acute myeloid leukemia

By          

Oncology Letters, Vol. 10, Iss. 1, 2015-01 ,pp. : 103-110

Spandidos Publications

Access to resources Recommend Favorite

A phase II study of docetaxel in patients with relapsed and refractory Ewing's Tumours

By Meyer T.   Mctiernan A.   Whelan J.  

Sarcoma, Vol. 7, Iss. 1, 2003-01 ,pp. : 13-17

Informa Healthcare

Access to resources Recommend Favorite

Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors

By Molife L.   Rudman Sarah   Alam Salma   Tan Daniel   Kristeleit Hartmut   Middleton Gary   Propper David   Bent Liz   Stopfer Peter   Uttenreuther-Fischer Martina   Wallenstein Gudrun   de Bono Johann   Spicer James  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 6, 2013-12 ,pp. : 1213-1222

Springer Publishing Company

Access to resources Recommend Favorite